Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PTGX

Protagonist Therapeutics Inc

Dollar change +1.32
Percentage change 2.82	%

Apr 02 • 04:00PM ET

48.20

+1.322.82%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN CRSP VRTX NTLA BLUE ARWR EDIT AKRO SGMO

| Held by: IJR IWM VTI VXF IJT XBI IWO SPSM AVUV IBB

Scroll to Statements

Index	RUT	P/E	11.46	EPS (ttm)	4.21	Insider Own	5.71%	Shs Outstand	61.04M	Perf Week	-2.74%
Market Cap	2.96B	Forward P/E	-	EPS next Y	-1.01	Insider Trans	-8.39%	Shs Float	57.88M	Perf Month	24.68%
Income	275.19M	PEG	-	EPS next Q	-0.06	Inst Own	100.08%	Short Float	8.86%	Perf Quarter	25.16%
Sales	434.43M	P/S	6.81	EPS this Y	-130.95%	Inst Trans	3.93%	Short Ratio	5.22	Perf Half Y	7.11%
Book/sh	11.06	P/B	4.36	EPS next Y	22.64%	ROA	49.81%	Short Interest	5.13M	Perf Year	70.44%
Cash/sh	6.82	P/C	7.06	EPS next 5Y	-	ROE	54.39%	52W Range	24.22 - 60.60	Perf YTD	24.87%
Dividend Est.	-	P/FCF	16.19	EPS past 5Y	-	ROI	40.14%	52W High	-20.46%	Beta	2.63
Dividend TTM	-	Quick Ratio	12.48	Sales past 5Y	2607.12%	Gross Margin	99.32%	52W Low	99.01%	ATR (14)	2.57
Dividend Ex-Date	-	Current Ratio	12.48	EPS Y/Y TTM	405.40%	Oper. Margin	58.20%	RSI (14)	51.16	Volatility	3.92% 5.54%
Employees	126	Debt/Eq	0.02	Sales Y/Y TTM	624.05%	Profit Margin	63.34%	Recom	1.18	Target Price	68.73
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	348.29%	Payout	0.00%	Rel Volume	1.25	Prev Close	46.88
Sales Surprise	28.92%	EPS Surprise	42.60%	Sales Q/Q	184.40%	Earnings	Feb 21 BMO	Avg Volume	982.34K	Price	48.20
SMA20	-5.76%	SMA50	11.74%	SMA200	16.01%	Trades		Volume	1,223,086	Change	2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	Goldman	Neutral	$47
Dec-06-24	Initiated	BMO Capital Markets	Outperform	$62
Nov-05-24	Initiated	Wedbush	Outperform	$58
Sep-24-24	Initiated	TD Cowen	Buy	$65
Sep-09-24	Initiated	Truist	Buy	$60
Oct-30-23	Initiated	CapitalOne	Overweight	$32
May-25-23	Resumed	Jefferies	Buy	$30 → $40
Aug-25-22	Initiated	JMP Securities	Mkt Outperform	$21
Feb-11-22	Initiated	BTIG Research	Buy	$55
Oct-12-21	Upgrade	JP Morgan	Neutral → Overweight	$49 → $55
Oct-11-21	Upgrade	Northland Capital	Market Perform → Outperform	$40
Sep-20-21	Downgrade	JP Morgan	Overweight → Neutral	$60 → $49
May-24-21	Initiated	Northland Capital	Outperform	$42
May-24-21	Initiated	JMP Securities	Mkt Outperform	$48
Jan-06-21	Initiated	JP Morgan	Overweight
Dec-16-20	Initiated	Piper Sandler	Overweight	$53
Sep-18-20	Reiterated	H.C. Wainwright	Buy	$28 → $33
Jul-15-20	Initiated	Jefferies	Buy	$27
May-18-20	Reiterated	H.C. Wainwright	Buy	$23 → $28
Jul-08-19	Initiated	H.C. Wainwright	Buy	$23

Show Previous Ratings

Apr-01-25 02:27PM	Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns (Seeking Alpha)
Mar-25-25 09:55AM	Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? (Zacks)
Mar-18-25 02:10PM	Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) Best Biotech Stock for 2025? (Insider Monkey)
07:00AM	These 10 biotech companies are changing how we discover new drugs and treat complex diseases (FastCompany)
07:00AM	Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 (ACCESSWIRE)
04:40PM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
Mar-15-25 04:40PM	Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? (Insider Monkey)
Mar-12-25 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why (Zacks)
Mar-11-25 09:29AM	Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success (GuruFocus.com) +6.81%
08:37AM	J&J and Protagonists icotrokinra scores in Phase IIb UC study (Clinical Trials Arena)
06:47AM	Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday (Insider Monkey)
Mar-10-25 04:30PM	Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out (Investor's Business Daily) +45.89%
08:15AM	Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis (ACCESSWIRE)
Mar-08-25 09:15AM	Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis (ACCESSWIRE)
Mar-03-25 12:01PM	Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer (Benzinga)
10:25AM	Takeda and Protagonist report topline outcomes from trial of rusfertide (Clinical Trials Arena)
06:45AM	Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.Finviz Elite
06:45AM	Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera (Business Wire)
06:29AM	Protagonist says Takeda-partnered drug succeeds in rare blood cancer (BioPharma Dive)
Feb-21-25 08:35AM	Protagonist Therapeutics (PTGX) Tops Q4 Earnings and Revenue Estimates (Zacks)
07:34AM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-12-25 07:51AM	Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Jan-31-25 07:00AM	Biotech walks a 'tightrope' amid unclear funding, regulations (Yahoo Finance Video)
Jan-29-25 06:15PM	Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025 (ACCESSWIRE)
Jan-06-25 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Dec-19-24 04:05PM	Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 (ACCESSWIRE)
Dec-09-24 04:05PM	Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting (ACCESSWIRE)
Dec-06-24 06:48AM	Protagonist Therapeutics price target raised to $58 from $43 at JMP Securities (TipRanks)
Nov-22-24 07:30AM	Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 (ACCESSWIRE) +11.55%
Nov-21-24 04:05PM	Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
Nov-19-24 07:30AM	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate (ACCESSWIRE)
04:30PM	Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.Finviz Elite
Nov-18-24 04:30PM	Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor (ACCESSWIRE)
Nov-13-24 12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-07-24 05:30PM	Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:56PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-05-24 04:05PM	Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting (ACCESSWIRE)
Oct-29-24 09:27AM	Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million (ACCESSWIRE)
Oct-18-24 06:28AM	Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases (Insider Monkey)
Oct-16-24 03:03PM	State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc (GuruFocus.com)
Sep-10-24 01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
Sep-03-24 07:30AM	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024 (ACCESSWIRE)
Aug-06-24 01:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Misses Revenue for Q2 2024 (InvestorPlace)
08:20AM	Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:18AM	Protagonist Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Aug-01-24 08:00AM	RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
07:00AM	Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports (ACCESSWIRE)
Jul-31-24 09:15AM	Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor (ACCESSWIRE)
Jul-22-24 07:00AM	Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 (ACCESSWIRE)
Jul-18-24 08:50AM	Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Jul-11-24 06:00AM	3 Growth Stocks No One Is Watching (But They Should Be) (InvestorPlace)
Jun-28-24 04:07PM	Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 (Investor's Business Daily) +8.69%
12:11PM	Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024 (Associated Press)
Jun-27-24 05:44PM	Protagonist Therapeutics Set to Join S&P SmallCap 600 (PR Newswire)
01:43PM	Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy? (Insider Monkey)
Jun-26-24 10:12PM	10 Best Healthcare Stocks to Buy Under $50 (Insider Monkey)
Jun-14-24 03:00AM	Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control (ACCESSWIRE)
Jun-05-24 01:35PM	The 3 Best Biotech Stocks to Buy in June 2024 (InvestorPlace) +16.10%
May-31-24 07:30AM	Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 (ACCESSWIRE)
May-14-24 04:05PM	Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress (ACCESSWIRE) +6.28%
May-07-24 11:53PM	PTGX Stock Earnings: Protagonist Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +5.12%
09:04PM	Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations (GuruFocus.com)
04:23PM	Protagonist Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:10PM	Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event (ACCESSWIRE)
04:05PM	Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update (ACCESSWIRE)
Apr-16-24 09:00AM	Turnstone Biologics Appoints William Waddill to its Board of Directors (GlobeNewswire)
Apr-05-24 12:00PM	All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy (Zacks)
Apr-03-24 01:52AM	Protagonist Therapeutics Inc CEO Sells 25,000 Shares (GuruFocus.com)
Mar-26-24 07:00AM	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data (ACCESSWIRE)
Mar-18-24 09:55AM	Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet (Zacks)
07:00AM	Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda (ACCESSWIRE)
Mar-11-24 07:00AM	Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year (ACCESSWIRE)
Mar-06-24 04:05PM	Protagonist Therapeutics to Participate in Upcoming Investor Conferences (ACCESSWIRE)
Mar-01-24 12:20PM	Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy? (Zacks) +5.83%
12:00PM	Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
12:00PM	Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice (Zacks)
09:55AM	Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade (Zacks)
08:50AM	Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why (Zacks)
Feb-27-24 04:38PM	Protagonist Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
Feb-21-24 05:00PM	New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera (ACCESSWIRE)
Feb-20-24 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
Feb-15-24 03:13AM	Steven Cohen Adjusts Position in Protagonist Therapeutics Inc (GuruFocus.com)
Feb-07-24 05:00PM	New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study (ACCESSWIRE)
Feb-02-24 01:03PM	Protagonist (PTGX) Up 14% on Licensing Deal With Takeda (Zacks) -7.12%
Feb-01-24 06:35AM	Takeda pays $300M to license Protagonist drug for blood disorder (BioPharma Dive) +14.03%
Jan-31-24 04:05PM	Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset (ACCESSWIRE)
Jan-29-24 07:30AM	Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 (ACCESSWIRE) +6.78%
Jan-12-24 03:02AM	Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX) (GuruFocus.com) +6.06%
Jan-03-24 07:30AM	Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (ACCESSWIRE)
Dec-16-23 11:01AM	Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ... (GuruFocus.com)
Dec-13-23 07:30AM	Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis (ACCESSWIRE)
Dec-12-23 09:04AM	Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals (ACCESSWIRE)
Nov-27-23 09:00AM	Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib (ACCESSWIRE)
Nov-16-23 04:05PM	Protagonist Therapeutics Reports Granting of Inducement Awards (ACCESSWIRE)
05:50AM	Looking for Stocks to Buy? Here Are the Companies Johnson & Johnson Is Betting the Most On (Motley Fool)
Nov-09-23 03:55PM	Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM) (ACCESSWIRE) -5.82%
09:55AM	Does Protagonist Therapeutics (PTGX) Have the Potential to Rally 141.08% as Wall Street Analysts Expect? (Zacks)
Nov-04-23 05:42AM	Protagonist Therapeutics Inc (PTGX) Reports Q3 2023 Financial Results (GuruFocus.com)
Nov-02-23 06:24PM	Protagonist Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) +8.05%

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Institutional Ownership

BlackRock, Inc.	16.59%
FARALLON CAPITAL MANAGEMENT LLC	9.95%
RTW INVESTMENTS, LP	9.23%
VANGUARD GROUP INC	7.08%
STATE STREET CORP	5.59%
JOHNSON & JOHNSON	4.11%
BVF INC/IL	3.19%
Pacer Advisors, Inc.	3.15%
Jefferies Financial Group Inc.	2.50%
PRICE T ROWE ASSOCIATES INC /MD/	2.34%

Income Statement • Balance Sheet • Cash Flow

Data

Timeframe

Period	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period End Date	—	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Period Length	12 Months	12 Months	12 Months	Upgrade your FINVIZ experience Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, historical statements, and much more. Learn more
Total Revenue	434.43	434.43	60.00
Cost of Goods Sold Incl. D&A	2.96	2.96	3.31
Gross Profit	431.47	431.47	56.69
Selling, General and Administrative Excl. Other	178.63	178.63	150.34
Research and Development	138.13	138.13	120.16
Other Operating Expense	0.00	0.00	0.00
Operating Income	252.84	252.84	-93.65
Interest Expense	0.00	0.00	0.00
Unusual Expense	0.00	0.00	0.00
Net Income Before Taxes	279.41	279.41	-78.95
Income Taxes	4.22	4.22	0.00
Consolidated Net Income	275.19	275.19	-78.95
Net Income From Continuing Operations	275.19	275.19	-78.95
Net Income	275.19	275.19	-78.95
EPS (Recurring)	4.14	4.23	-1.39
EPS (Basic, Before Extraordinaries)	4.48	4.47	-1.39
EPS (Diluted)	4.21	4.23	-1.39
EBITDA	255.81	255.81	-90.34
Price To Earnings Ratio	11.46	11.46	14.45
Price To Sales Ratio	5.90	5.78	21.69
Gross Margin	99.32	99.32	94.48
Operating Margin	58.20	58.20	-156.09
Net Margin	63.34	63.34	-131.59
Shares Outstanding	61.04	61.04	57.71
Market Capitalization	2,958.72	2,958.72	2,295.12

Insider Trading Volume

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Waddill William D.	Director	Mar 17 '25	Sale	54.25	4,000	217,000	13,130	Mar 19 04:01 PM
WILLIAM D WADDILL	Director	Mar 17 '25	Proposed Sale	54.78	4,000	219,120		Mar 17 04:30 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Option Exercise	24.48	30,514	746,956	114,406	Mar 14 06:21 PM
MOLINA ARTURO MD	Chief Medical Officer	Mar 13 '25	Sale	55.74	30,514	1,700,850	83,892	Mar 14 06:21 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Option Exercise	14.90	24,903	371,164	87,724	Mar 14 06:20 PM
Ali Asif	Chief Financial Officer	Mar 12 '25	Sale	58.73	24,903	1,462,553	62,821	Mar 14 06:20 PM
MOLINA ARTURO MD	Officer	Mar 13 '25	Proposed Sale	55.00	30,514	1,678,270		Mar 13 05:24 PM
Ali Asif	Officer	Mar 12 '25	Proposed Sale	58.73	24,903	1,462,587		Mar 12 05:31 PM
PATEL DINESH V PH D	President and CEO	Mar 05 '25	Option Exercise	4.21	24,000	101,040	564,260	Mar 05 08:02 PM
PATEL DINESH V PH D	President and CEO	Feb 19 '25	Sale	38.18	5,359	204,607	540,260	Feb 20 05:25 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Option Exercise	8.04	26,000	209,040	62,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Option Exercise	8.04	5,529	44,453	51,973	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 27 '24	Sale	44.70	26,000	1,162,280	46,444	Nov 27 07:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 26 '24	Sale	45.60	5,529	252,122	46,444	Nov 27 07:11 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Option Exercise	7.75	175,000	1,356,000	359,611	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Option Exercise	12.17	30,450	370,576	286,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 25 '24	Sale	46.04	103,437	4,762,239	256,174	Nov 27 07:09 PM
Gupta Suneel	Chief Development Officer	Nov 26 '24	Sale	45.50	19,191	873,190	266,983	Nov 27 07:09 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Option Exercise	21.58	1,727	37,269	429,935	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 25 '24	Sale	46.96	78,520	3,687,299	435,208	Nov 27 07:08 PM
PATEL DINESH V PH D	President and CEO	Nov 26 '24	Sale	46.25	21,480	993,450	408,455	Nov 27 07:08 PM
MOLINA ARTURO MD	Officer	Nov 27 '24	Proposed Sale	44.00	16,000	704,000		Nov 27 04:39 PM
MOLINA ARTURO MD	Officer	Nov 26 '24	Proposed Sale	45.00	16,000	720,000		Nov 26 07:39 PM
Gupta Suneel	Officer	Nov 26 '24	Proposed Sale	45.50	19,191	873,184		Nov 26 07:37 PM
Gupta Suneel	Officer	Nov 25 '24	Proposed Sale	46.46	103,437	4,805,683		Nov 25 05:40 PM
Dinesh Patel	CEO	Nov 25 '24	Proposed Sale	45.93	100,000	4,593,000		Nov 25 04:11 PM
MOLINA ARTURO MD	Chief Medical Officer	Nov 15 '24	Sale	40.98	1,906	78,108	46,444	Nov 19 06:49 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Option Exercise	15.68	12,000	188,160	46,960	Sep 13 04:35 PM
Ali Asif	Chief Financial Officer	Sep 11 '24	Sale	44.49	14,203	631,872	34,960	Sep 13 04:35 PM
Waddill William D.	Director	Sep 10 '24	Option Exercise	12.88	8,000	103,040	20,000	Sep 12 07:38 PM
Waddill William D.	Director	Sep 10 '24	Sale	45.00	8,000	360,000	12,000	Sep 12 07:38 PM
Ali Asif	Officer	Sep 11 '24	Proposed Sale	44.49	14,203	631,855		Sep 11 06:15 PM
WILLIAM D WADDILL	Director	Sep 10 '24	Proposed Sale	45.00	8,000	360,000		Sep 10 04:17 PM
Waddill William D.	Director	Jul 24 '24	Option Exercise	12.88	8,000	103,040	20,000	Jul 26 04:31 PM
Waddill William D.	Director	Jul 24 '24	Sale	40.00	8,000	320,000	12,000	Jul 26 04:31 PM
Waddill William D.	Director	Jun 07 '24	Option Exercise	12.88	8,000	103,040	20,000	Jun 11 04:30 PM
Waddill William D.	Director	Jun 07 '24	Sale	35.00	8,000	280,000	12,000	Jun 11 04:30 PM
PATEL DINESH V PH D	President and CEO	Jun 07 '24	Sale	35.19	35,000	1,231,650	515,415	Jun 11 04:30 PM
Ali Asif	Chief Financial Officer	Apr 18 '24	Sale	25.11	1,234	30,986	37,163	Apr 19 08:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTGX

Protagonist Therapeutics Inc

Institutional Ownership

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience

Upgrade your FINVIZ experience